Ziltivekimab ELISA Kit

Ziltivekimab, a novel human IgG1, k antibody directed against IL-6 ligand, may improve inflammation and hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in patients receiving maintenance hemodialysis (HD), according to new study findings.

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.